Abstract
An aryl p-(trifluoromethyl) substituent increases the affinity of 1,3-disubstituted 8-phenylxanthines at A2a-adenosine receptors, while having little effect on affinity at A1-adenosine receptors. In contrast, an aryl p-(trifluoromethyl) substituent has little effect on affinity of 3,7-disubstituted and 1,3,7-trisubstituted 8-phenylxanthines. An aryl p-sulfo substituent reduces affinity of all 8-phenylxanthines at A1- and A2a-adenosine receptors. An 8-(trifluoromethyl) substituent markedly reduces affinity of 1,3-dialkylxanthines at both A1 and A2a-adenosine receptors. In contrast, 8-(trifluoromethyl) caffeine retains affinity for A2a-adenosine receptors, but does lose affinity for A1-adenosine receptors. 8-Bromo-, 8-acryl-, and 8-pent-1-enylcaffeines are also selective for A2-adenosine receptors, while 8-cyclobutylcaffeine is nonselective. 8-[trans-2-(tert-butyloxycarbonyl) vinylcaffeine is 20-fold selective for Aza vs A1 receptors.
Structure–activity relationships for xanthines as adenosine receptor antagonists have been studied extensively over the last 2 decades.1 High potency in xanthines that retain moderate water solubility and, hence, bioavailability and high selectivity for different classes of adenosine receptors have been the goals of such studies. Addition of an 8-phenyl substituent, particularly for 1,3-dipropylxanthines, yields extremely potent compounds with high selectivity for A1-adenosine receptors.2–13 Unfortunately, many of these 8-phenylxanthines have extremely low water solubility and hence poor bioavailability.14 The 8-cycloalkylxanthines proved to be more water soluble and to be both very potent and selective for A1-adenosine receptors. Xanthines with high selectivity for A2-adenosine receptors had not been forthcoming, although certain 1,3,7-trisubstituted xanthines exhibited modest selectivity for A2-adenosine receptors.15,16 Recently certain 8-styryl-1,3,7-trisubstituted xanthines were reported to be highly selective for A2-adenosine receptors.17,18
The effects of aryl substituents on the potency and selectivity of 8-phenyltheophylline have been analyzed. In one study on bovine brain A1 receptors a quantitative structure–activity analysis for 45 aryl-substituted 8-phenyltheophyllines was presented.4 This study was preceded by a more limited exploration of structure–activity relationships for aryl substituted 8-phenyltheophyllines.3 Small electron-donating substituents at the ortho-position increased potency, while effects of para-substituents on activity were not readily correlated with electronic or steric effects or lipophilicity. Meta-substituents tended to decrease activity. Polar substituents such as p-sulfo or p-carboxy that are electron-withdrawing reduced potency at both A1- and A2-adenosine receptors, while conferring high water solubility.5 Such xanthines have proven useful as peripheral adenosine receptor antagonists.16,19
The effects of xanthine substituents other than aryl at the 8-position have not been studied extensively. 8-Cycloalkyl-1,3-dialkylxanthines are potent and selective antagonists for A1-adenosine receptors.9,10,11,13 8-Cycloalkyl-1,3,7-trialkylxanthines11 and 8-styryl-1,3,7-trialkylxanthines17,18 are selective antagonists for A2-adenosine receptors.
The present study examines the effects at adenosine receptors of the electron-withdrawing trifluoromethyl group, either in the 8-position or in the para-position of 8-phenylxanthines and various other groups, such as halo, alkyl, or vinyl at the 8-position. Increases in potency at A2-adenosine receptors occur on aryl p-(trifluoromethyl) substitution of certain 8-phenylxanthines. Various 8-substituted caffeines, including 8-(trifluoromethyl) caffeine and 8-vinylcaffeines are somewhat selective for A2-adenosine receptors.
Chemistry
Synthesis of xanthines substituted at 1-, 3-, 7-, and 8-positions (Tables I and II) involved the acylation of appropriate 5,6-diaminouracil to afford 5-(acylamino)-6-aminouracils (e.g. 40–44), which were then cyclized to the 8-arylxanthines (2, 5, 8, 9, 11), and 8-cycloalkylxanthine (25), or an 8-vinylxanthine (26) by sodium hydroxide. The 8-(p-sulfonamidophenyl)xanthine 11 was converted to the corresonding 8-(p-sulfophenyl)xanthine 10 with NaNO2 in trifluoroacetic acid. Certain 1,3,7-trisubstituted 8-phenylxanthines (13, 15–19) were prepared by alkylation of the appropriate disubstituted 8-phenylxanthine. 8-(Trifluoromethyl)-1,3-di-n-propylxanthine (29) and the corresponding theophylline derivative (22) were obtained directly from the diaminouracil after refluxing with trifluoroacetic acid and subsequent cyclization under basic conditions. An 8-acrylcaffeine derivative (39) was synthesized from 8-bromocaffeine and tert-butyl acrylate using the Heck reaction (Scheme I).25 The tert-butyl ester was cleaved in trifluoroacetic acid to provide a carboxylic congener (38).
Table I.
Effect of Aryl Trifluorometyl and Sulfo Substituents on Activity of 8-Phenylxanthines at Adenosine Receptors of Rat Brain Membranes
|
Ki (μM) or % inhibna |
|||
|---|---|---|---|
| no. | xanthine substituents | A1-binding, [3H]PIA | A2a-binding, [3H]CGS 21680 |
|
| |||
| 1 | 1,3-dimethyl-8-phenyl | 0.076 ± 0.012 | 0.97 ± 0.06 |
| 2 | 1,3-dimethyl-8-[p-(trifluoromethyl)phenyl] | 0.15 ± 0.02 | 0.21 ± 0.02 |
| 3 | 1,3-dimethyl-8-(p-sulfophenyl) | 1.0 ± 0.23 | 5.8 ± 0.7 |
| 4 | 1,3-dipropyl-8-phenyl | 0.010 ± 0.004 | 0.14 ± 0.01 |
| 5 | 1,3-dipropyl-8-[p-(trifluoromethyl)phenyl] | 0.0075 ± 0.0005 | 0.042 ± 0.004 |
| 6 | 1,3-dipropyl-8-(p-sulfophenyl) | 0.14 ± 0.04 | 0.79 ± 0.08 |
| 7 | 1,3-dipropyl-8-(p-sulfonamidophenyl) | 0.0085 ± 0.0011 | 0.075 ± 0.009 |
| 8 | 3,7-dimethyl-8-phenyl | 3.4 ± 0.2 | 12 ± 1 |
| 9 | 3,7-dimethyl-8-[p-(trifluoromethyl)phenyl] | 3.7 ± 0.2 | 10% (20 mM) |
| 10 | 3,7-dimethyl-8-(p-8ulfophenyl) | 1.8% (250 μM) | 0% (250 μM) |
| 11 | 3,7-dimethyl-8-(p-sulfonamidophenyl) | 33% (250 μM) | 42 (250 μM) |
| 12 | 8-phenyl-1,3,7-trimethyl | 15 ± 3 | 16 ± 1 |
| 13 | 8-[p-(trifluoromethyl)phenyl]-1,3,7-trimethyl | 17 ± 2 | 16 ± 1 |
| 14 | 8-(p-sulfophenyl)-1,3,7-trimethyl | 3.3% (250 μM) | 20 ± 1 |
| 15 | 1-sdlyl-3,7-dimethyl-8-phenyl | 9.0 ± 0.1 | 12 ± 1 |
| 16 | 1-allyl-3,7-dimethyl-8-[p-(trifluoromethyl)phenyl] | 5.7 ± 0.9 | 11 ± 1 |
| 17 | 1-allyl-3,7-dimethyl-8-(p-sulfophenyl) | 35% (250 μM) | 27 ± 4 |
| 18 | 1,7-diallyl-3-methyl-8-phenyl | 0.66 ± 0.15 | 7.7 ± 0.5 |
| 19 | 7-allyl-1,3-dipropyl-8-[p-(trifluoromethyl)phenyl] | 2.9 ± 0.1 | 4.2 ± 0.5 |
Values are means ± SEM (n = 3) or are percent inhibition at highest concentration tested. The highest concentration is given in parentheses. In some cases higher concentrations could not be tested because of solubility.
Table II.
Effect of 8-(Trifluorometbyl), 8-Methyl, 8-Halo, and 8-Vinyl Substituents on Affinity of Xanthines at Adenosine Receptors of Rat Brain Membranes
|
K1 (μM) or % inhibna |
|||
|---|---|---|---|
| no. | substituents | A1 binding, [3H]PIA | A2a-binding, [3H[CGS 21680 |
|
| |||
| Substituted Theophylline | |||
| 20 | none | 14 ± 3 | 8.0 ± 1.3 |
| 21 | 8-methyl | 8.8 ± 3.0 | 34% (250 μM) |
| 22 | 8-(trifluoromethyl) | 0% (250 μM) | 0% (250 μM) |
| 23 | 8-chloro | 39% (250 μM) | 34 (100 μM) |
| 24 | 8-bromo | 10.2 ± 0.2 | 36% (100 μM) |
| 25 | 8-cyclobutyl | 0.19 ± 0.01 | 2.8 ± 0.1 |
| 26 | 8-pent-1-enyl | 0.38 ± 0.05 | 0.44 ± 0.03 |
| Substituted Xanthine | |||
| 27 | 3-isobutyl-1-methyl | 7 ± 21 | 5.8 ± 1.1 |
| 28 | 8-bromo-3-isobutyl-1-methyl | 65 ± 21 | 10% (100 μM) |
| 29 | 1,3-dipropyl | 0.7 ± 0.3 | 2.6 ± 0.2 |
| 30 | 1,3-dipropyl-8-methyl | 0.6 ± 0.1 | 2.8 ± 0.2 |
| 31 | 1,3-dipropyl-8-(trifluoromethyl) | 4.5% (20 μM) | 4.3% (20 μM) |
| Substituted Caffeine | |||
| 32 | none | 29 ± 6 | 23 ± 2 |
| 33 | 8-methyl | 4.9 ± 0.3 | 7.6 ± 0.8 |
| 34 | 8-(trifluoromethyl) | 8% (100 μM) | 29 ± 2 |
| 35 | 8-bromo | 49 ± 5 | 12 ± 1 |
| 36 | 8-cyclobutyl | 30 ± 2 | 19 ± 1 |
| 37 | 8-pent-1-enyl | 9.1 ± 0.4 | 1.6 ± 0.1 |
| 38 | 8-(trans-2-carboxyvinyl) | 3% (100 μM) | 42 ±7 |
| 39 | 8-[trans-2-(tert-butyloxycarbonyl) vinyl] | 12 ± 2 | 0.61 ± 0.09 |
Values are means ± SEM (n = 3) or are percent inhibition at highest concentration tested. See legend of Table I.
Scheme I.

Synthesis of 8-Acrylxanthine Derivatives via the Heck Reaction
Results and Discussion
1,3-Dimethyl-8-phenylxanthine (8-phenyltheophylline, 1) is widely used as a potent adenosine receptor antagonist, which is somewhat selective (~13-fold) for A1-receptors. The presence of an electron-withdrawing p-(trifluoromethyl) substituent has little effect on affinity at rat brain A1-receptors, but increases activity at rat brain A2a-receptors by about 5-fold (Table I), resulting in a potent, but now nonselective, antagonist (2).
The effect of aryl substituents on the activity of 1,3-dimethyl-8-phenylxanthmes at A1-receptors has been studied.3,4 Electron-donating substituents (hydroxy, amino) in the ortho-position appear to increase activity at A1-receptors.4 Correlations of activity with electronic or steric effects or lipophilicity of para-substituents were not clear.4 At rat striatal A2a-receptors p-amino, p-chloro, and p-methoxy substituents all increased the potency of 1,3-dimethyl-8-phenylxanthine by about 2-fold.9 At both A1- and A2a-receptors, an anionic para-substituent (COO−, -SO3−) markedly decreased potency.4,7,9 In the present study, a p-(trifluoromethyl) group had the same effects on activity for 1,3-dipropyl-8-phenylxanthine (5 vs 4) as it had for 8-phenyltheophylline (2 vs 1), namely little effect on affinity at A1-receptors and about a 3-fold increase in affinity at A2a receptors (Table I).
3,7-Dimethyl-8-phenylxanthine, 8, proved to be relatively weak, compared to 1,3-disubstituted 8-phenylxanthines (e.g. 1) as an adenosine receptor antagonist (Table I). A p-(trifluoromethyl) substituent decreased affinity at A2a-receptors (9 vs 8).
1,3,7-Trisubstituted 8-phenylxanthines, such as 8-phenylcaffeine, 12, are relatively weak, compared to 1,3-disubstituted 8-phenylxanthines, as adenosine receptor antagonists.11 The effects of aryl substituents on activity have not been probed. In the present study, an electron-withdrawing p-(trifluoromethyl) group had little effect on affinity of either 8-phenyl-1,3,7-trimethylxanthine (8-phenylcaffeine) (13 vs 12) or of 1-allyl-3,7-dimethyl-8-phenylxanthine (16 vs 15). A p-(trifluoromethyl) substituent did decrease affinity of 1,7-diallyl-3-methyl-8-phenylxanthine (19 vs 18) at A1-receptors by about 4-fold.
Among the 8-[p-(trifluoromethyl)phenyl]xanthines in this study, no compounds were developed that have any particular advantage in A1-selectivity or potency over the corresponding 8-phenylxanthine, and the trifluoromethyl group would be expected to cause an undesirable reduction in water solubility.
In contrast, the high water solubility conferred by an aryl sulfo substituent has made 1,3-dimethyl-8-(p-sulfophenyl)xanthine [8-(p-sulfophenyl)theophylline, 3] and 1,3-dipropyl 8-(p-sulfophenyl)xanthine, 6, useful research tools since they do not penetrate into cells20 or cross the blood–brain barrier.21 Both are relatively weak, compared to the parent 8-phenylxanthines, as adenosine receptor antagonists, and both (3 and 6) are only modestly A1-selective (Table I). An aryl sulfonamido substituent does not decrease activity of 1,3-dipropyl-8-phenylxanthine (7 vs 9). The resulting xanthine, 7, is nearly as A1-selective as the parent xanthine and might be more water soluble. In the 3,7-disubstituted and 1,3,7-trisubstituted 8-phenylxanthines, an aryl sulfo (or sulfonamido) substituent (10, 14, 17) also markedly reduces affinity at adenosine receptors. The 8-(p-sulfophenyl)-1,3,7-trimethylxanthine [8-(p-sulfophenyl) caffeine, 14] is somewhat selective for the rat brain A2a-receptor, compared to the rat brain A1-receptor (Table I). However, in other A1- and A2-receptor comparisons the selectivity for 14 for A2a-receptors was not apparent.11
Effects of substituents other than aryl, cycloalkyl, or aralkyl at the 8-position on activity of xanthines at adenosine receptors have received little attention.2,13 An 8-methyl group (21, 30, 33) slightly increases the affinity of theophylline, 1,3-dipropylxanthine, and caffeine at rat brain A1-receptors, while either reducing (21), increasing (33), or having little effect (30) on affinity at rat brain A2a-receptors (Table I). An 8-(trifluoromethyl) substituent (22, 31) nearly eliminates affinity of theophylline and 1,3-dipropylxanthine at both A1- and A2-receptors. 3-Isobutyl-1-methyl-8-(trifluoromethyl)xanthine was previously reported to have very low potency at A1- and A2a-receptors.13 An 8-(trifluoromethyl) substituent (34) also reduces the affinity of caffeine at A1-receptors, while having virtually no effect on its affinity at A2a-receptors (Table II). 8-Halo substituents (Cl, Br) markedly reduce affinity of 1,3-disubstituted xanthines at adenosine receptors with the exception of 8-bromotheophylline (24), which has a slightly higher affinity at A1 receptors than theophylline (Table II). 8-Bromocaffeine, 35, has a slightly higher affinity than caffeine at both A1 and A2a receptors. An 8-cyclobutyl substituent (25) markedly increases affinity of theophylline for adenosine receptors (Table II), as was the case for 8-cyclopentyl- and 8-cyclohexyltheophyllines,9,10,13 but the degree of A1-selectivity (15-fold) is not as large as for 8-cyclopentyltheophylline.9 8-Pent-1-enyltheophylline, 26, is a potent antagonist, but unlike the 8-cycloalkyltheophyllines, is not selective for A1 receptors (Table II). In contrast, an 8-cyclobutyl substituent (36) has virtually no effect on the affinity of caffeine at adenosine receptors, and the 8-pent-1-enylcaffeine, 37, shows a slight selectivity (6-fold) for A2a receptors (Table II). In view of the marked A2-selectivity of 8-styrylcaffeines,17,18 two 8-acryl derivatives of caffeine, namely the water soluble 8-(trans-2-carboxyvinyl) caffeine, 38, and 8-[trans-2-(tert-butylox-ycarbonyl) vinyl]caffeine 39 were prepared. Both were A2-selective (Table II). The 20-fold selectivity of 39 suggests that the functionalized congener approach6 could be applied to such caffeines to develop a range of selective A2-antagonists, e.g. esters and other derivatives of the carboxylic congener 38. The A2-selectivity of 8-vinylcaffeine derivatives demonstrates that a phenyl group, as in the structurally similar, A2-selective 1,3,7-trialkyl-8-styrylxanthines,17,18 is not required for this selectivity. The Pdcatalyzed Heck reaction25 represents a new approach to 8-substitution, especially 8-vinyl substitution, of xanthines.
The present study indicates that the presence of 8-substituents, including a p-(trifluoromethyl) group on an 8-phenyl and 8-methyl, 8-(trifluoromethyl), 8-halo, 8-cycloalkyl, 8-pent-1-enyl and 8-acryl groups, can have markedly different effects on affinity for adenosine receptors when the xanthine is a caffeine analog (1,3,7-substituted) rather than a theophylline analog (1,3-substituted). Such differences suggest either that caffeine analogs bind differently than theophylline analogs to adenosine receptors or that the conformational effects of 7- and 8-position substituents are interdependent. 8-Substituted caffeine analogs, including the 8-styryl compounds7,18 and the present 8-acryl compounds (Table II), appear likely to provide long-sought potent and selective A2-receptor antagonists.
Experimental Section
Chemistry.
Compounds 1, 3, 4, 6, 7, 14 were synthesized as reported5,10,11 or were obtained from Research Biochemicals International (Natick MA). CHN analysis (±0.4% acceptable) were obtained for new compounds synthesized (2, 5, 8, 9–11, 13, 15–19, 22, 25, 26, 29, 32, 36, 37–39, 40–44). All melting points were determined without correction using a Gallenkamp apparatus. UV/vis spectra were done with a Perkin-Elmer, Lambda 5 spectrometer; λmax is reported in nanometers (log ϵ). 1H-NMR spectra were determined with a Bruker WM-250 and are reported as δ in ppm relative to TMS as internal standard.
8-[4-(Trifluoromethyl)phenyl]-1,3-dimethylxanthine (2).
6-Amino-5-[[4-(trifluoromethyl)benzoyl]amino]-1,3-dimethyluracil (40, 2.5 g) was refluxed in 40 mL of 1 N NaOH and 10 mL of EtOH for 1 h. The hot solution was acidified with AcOH, and the precipitate was collected after cooling. Recrystallization from MeOH gave 1.68 g (71%) of colorless crystals. Mp: >350°C. UV (MeOH): 225 sh (4.25), 236 (4.32), 264 sh (3.70), 318 (4.32).
8-[4-(Trifluoromethyl)phenyl]-1,3-di-n-propylxanthine (5).
6-Amino-5-[[4-(trifluoromethyl)benzoyl]amino]-1,3-di-n-propyluracil (41, 2.0 g) was refluxed in 50 mL of 2 N NaOH and 10 mL of EtOH for 1 h. The hot solution was acidified with AcOH, and after cooling, the precipitate was collected, washed with water, and dried at 100 °C to give 1.48 g (78%) of chromatographically pure crystals. Mp: 259–261 °C. UV (MeOH): 202 (4.32), 238 (4.29), 318 (4.29).
3,7-Dimethyl-8-phenylxanthine (8).
6-Amino-5-benzoyl-N-(methylamino)-1-methyluracil (43, 17 g, 70 mmol) was refluxed in 150 mL of 2 N NaOH and 50 mL of EtOH for 1 h. The hot solution was diluted with 200 mL of H2O and then acidified with AcOH to give a colorless precipitate. After drying at 100 °C, 15.6 g (93%) of a chromatographically pure solid (mp: >300 °C) was obtained. UV (MeOH): 205 (4.33), 229 (4.23), 2.93 (4.11).
8-[4-(Trifluoromethyl)phenyl]-3,7-dimethylxanthine (9).
6-Amino-5-(4-trifluoromethylbenzoyl)-N-(methylamino)-1-methyluracil (42, 6.84 g, 20 mmol) was refluxed in 100 mL of 2 N NaOH and 20 mL of EtOH for 1 h. The hot solution was acidified with AcOH, and after cooling, the solid was collected to give 5.6 g (86%) of chromatographically pure crystals. Mp: 304–305 °C. UV (MeOH): 205 (4.36), 222 (4.31), 230 sh (4.28), 303 (4.15).
3,7-Dimethyl-8-(4-sulfophenyl)xanthine (10).
3,7-Dimethyl-8-(4-sulfonamidophenyl)xanthine (11, 16.75 g, 0.05 mol) was dissolved in 300 mL of trifluoroacetic acid, and then at room temperature a solution of 5 g of NaNO2 in 10 mL of water was added dropwise with stirring. The reaction was diluted with 200 mL of H2O and then stirred for another 2 h to form a crystalline precipitate. The chromatographically pure product was dried to provide 16.1 g (95%) of a crystalline powder. Mp: >300 °C. UV (pH 2): 228 sh (4.32), 235 (4.33), 297 (4.24).
3,7-Dimethyl-8-(4-sulfoamidophenyl)xanthine (11).
6-Amino-5-(4-sulfonamidobenzoyl)-N-(methylamino)-1-methyluracil (44, 25 g, 71 mmol) was refluxed in 150 mL of 2 N NaOH and 50 mL of EtOH for 1 h. The hot solution was diluted with 200 L of H2O and then acidified with AcOH to form a colorless precipitate. After drying, 21.4 g (90%) of a chromatographically pure, crystalline powder (mp: >300 °C) was obtained. UV (pH 1): 228 (4.31), 235 sh (4.31), 301 (4.21).
8-[4-(Trifluoromethyl)phenyl]-1,3,7-trimethylxanthine (13).
8-[4-(Trifluoromethyl)phenyl]-1,3-dimethylxanthine (2, 1.63 g, 6 mmol) was treated in 100 mL of DMF with 3 g of K2CO3 and 5 mL of methyl iodide for 3 h with stirring at room temperature. The inorganic salts were filtered off, the filtrate was evaporated to dryness, and the residue was treated with 15 mL of water. The crystalline solid was recrystallized from MeOH to give 1.56 g (92%) of colorless crystals. Mp: 180–182 °C. UV (MeOH): 203 (4.30), 224 (4.28), 302 (4.16).
1-Allyl-3,7-dimethyl-8-phenylxanthine (15).
A solution of 3,7-dimethyl-8-phenylxanthine (8, 15 g, 59 mmol) in 500 mL of DMF was treated with 45 g of K2CO3 and allyl iodide (14.4 g, 86 mmol) at 50 °C for 4 h with stirring. After cooling, the inorganic salts were filtered off, and the filtrate was reduced in volume by evaporation in vacuo. The residue was treated with 200 mL of H2O to give a colorless solid, which on recrystallization from H2O/EtOH gave 14.8 g (85%) colorless crystals. Mp: 177–178 °C. UV (MeOH): 230 (4.34), 293 (4.22).
1-Allyl-8-[4-((trifluoromethyl)phenyl]-3,7-dimethylxanthine (16).
A solution of 8-[4-(trifluoromethyl)phenyl]-3,7-dimethylxanthine (9, 1.62 g, 5 mmol) in 100 mL of DMF was treated with 3 g of K2CO3 and allyl iodide (1.5 g) at room temperature for 3 h with stirring. The inorganic salts were filtered off, the filtrate was evaporated to dryness, and the residue was treated with 50 mL of H2O to give a colorless solid. Recrystallization from H2O/EtOH gave 1.55 g (85%) of colorless crystals. Mp: 150–152 °C. UV (MeOH): 204 (4.34), 223 (4.32), 230 sh (4.30), 303 (4.17).
1-Allyl-3,7-dimethyl-8-(4-sulfophenyl)xanthine (17).
A suspension of 10 (16.7 g, 0.05 mol) in 300 mL of DMF was treated with 5 g of sodium hydride and 25 g of allyl iodide at room temperature for 8 h. The inorganic salts were filtered off, and the filtrate was evaporated to dryness. The residue was treated with 100 mL of acetone, to give a solid, which was recrystallized from 50 mL of 5 N HCl to give 13.6 g (73%) of colorless crystals. Mp: >300 °C. UV (pH 13): 203 (4.42), 235 (4.36), 298 (4.26).
1,7-Diallyl-3-methyl-8-phenylxanthine (18).
A mixture of 3-methyl-8-phenylxanthine (2.42 g, 10 mmol) and 9 g of K2CO3 was treated in 100 mL of DMF with allyl iodide (4 g) at 50 °C with stirring for 3 h. The inorganic salts were filtered off, the filtrate was evaporated to dryness, and the residue was recrystallized from H2O/MeOH to give 2.4 g (75%) of colorless crystals. Mp: 104–106 °C. UV (MeOH): 204 (4.44), 230 (4.33), 293 (4.20).
7-Allyl-8-[4-(trifluoromethyl)phenyl]-1,3-di-n-propylxanthine (19).
A mixture of 8-[4-((trifluoromethyl)phenyl]-1,3-di-n-propylxanthine (5, 1.62 g, 4.3 mmol) and 3 g of K2CO3 were treated in 100 mL of DMF with 2 g of allyl iodide at room temperature with stirring for 3 h. The inorganic salts were filtered off, the filtrate was evaporated to dryness, and the residue was treated with 50 mL of water. The precipitate was recrystallized from H2O/EtOH to give 1.4 g (80%) of colorless crystals. Mp: 63–65 °C. UV (MeOH): 205 (4.36), 222 (4.32), 230 sh (4.29), 302 (4.11).
8-(Trifluoromethyl)theophylline (22).
5,6-Diamino-1,3-dimethyluracil (8.5 g, 0.05 mol) was refluxed in 50 mL of trifluoroacetic anhydride for 20 min. The reaction mixture was evaporated to dryness and the residue treated with 20 mL of 2 N NaOH for 30 min under reflux. The hot solution was acidified to pH 3 and the precipitate collected after cooling. The colorless crystals were recrystallized from a mixture of H2O/EtOH (3:2) to give 9.07 g (73%) of colorless crystals. Mp: 268–270 °C. UV (pH 13): 216 (4.03), 235 sh (3.61), 274 (4.08). 1H NMR (DMSO-d6): δ 3.4 (s, 3H, NCH3), 3.51 (s, 3H, NCH3), 13.8 (s, 1H, NH).
8-Cyclobutyl-1,3-dimethylxanthine (25).
Compound 25 was made from cyclobutanoic acid according to the general procedure A given in ref 18 in 28% yield. Mp: >300 °C dec. 1H NMR (DMSO-d6): δ 1.8–2.1 (m, 2H, CH2, 3 of Bu), 2.3 (m, 4H, CH2, C2 and C4 of Bu), 3.23 (s, 3H, NCH3), 3.43 (s, 3H, NCH3), 3.58 (m, 1H, Cl of Bu). MS (EI): m/e 234, 206.
trans-8-Pent-1-enyl-1,3-dimethylxanthine (26).
Compound 26 was made from trans-2-hexenoic acid according to the general procedure A given in ref 18 in 8% yield and recrystallized from DMF/water. Mp: 218–223 °C dec. 1H NMR (DMSO-d6): δ 0.91 (t, 3H, CH3), 1.46 (m, 2H, CH2), 2.20 (q, 2H, CH2, J = 7 Hz), 3.22 (s, 3H, NCH3), 3.42 (s, 3H, NCH3), 6.27 (d, 1H, J = 16 Hz), 6.81 (dt, 1H, J = 16 Hz, J = 7 Hz). MS (CI NH3): m/e 266 (MNH4+, base), 241 (MH+).
8-(Trifluoromethyl)-1,3-di-n-propylxanthine (29).
5,6-Diamino-1,3-di-n-propyluracil (4 g, 0.018 mol) was refluxed in 40 mL of trifluoroacetic anhydride for 1 h. The reaction mixture was evaporated to dryness, the residue was treated with 50 mL of 2 N NaOH under reflux for 30 min, and then acidified to pH 4, and the crystalline precipitate was collected. Recrystallization from H2O/EtOH gave 4.3 g (80%) of colorless crystals. Mp: 172 °C. UV (pH 13): 216 (4.06), 235 sh (3.58), 275 (4.05).
8-(Trifluoromethyl) caffeine (32).
8-(Trifluoromethyl)-theophylline (22, 2.48 g, 0.01 mol) was dissolved in DMF (60 mL) and then K2CO3 (7.5 g, 0.05 mol) and methyl iodide (2.11 g, 0.015 mol) added and stirred for 2 h at room temperature. The insoluble inorganic salts were filtered off, the fíltrate was evaporated to dryness, and the residue was recrystallized from H2O/EtOH (4:1) to give 2.18 g (83%) of colorless crystals. Mp: 131–133 °C. UV (MeOH): 207 (4.39), 232 sh (3.64), 281 (3.92). 1H NMR (DMSO-d6): δ 4.12, 3.55, 3.38 (each s, 3H, NCH3). MS (EI): m/e 262, 193, 177.
8-Cyclobutyl-1,3,7-trimethylxanthine (36).
Compound 36 was made from compound 25 according to procedure B given in ref 18. It was recrystallized from DMF/water (72% yield). Mp: 181–183 °C. MS (EI): m/e 248, 220.
trans-8-Pent-1-enyl-1,3,7-trimethylxanthine (37).
Compound 37 was made from compound 26 according to procedure B given in ref 18. It was recrystallized from DMF/water (64% yield). Mp: 142–143 °C. 1H NMR (DMSO-d6): δ 0.92 (t, 3H, CH3), 1.50 (m, 2H, CH2), 2.26 (q, 2H, J = 7 Hz), 3.21 (s, 3H, NCH3), 3.41 (s, 3H, NCH3), 3.89 (s, 3H, N7CH3), 6.57 (d, 1H, J = 16 Hz), 6.86 (dt, 1H, J = 16 Hz, J = 7 Hz). MS (EI): m/e 262, 247 (M – CH3, base).
8-(trans-2-Carboxyvinyl)-1,3,7-trimethylxanthine (38).
Compound 39 (76 mg, 238 μmol) was dissolved in 3 mL of trifluoroacetic acid and stirred for 1 h. After evaporation, the residue was triturated with ether to provide the pure product (55 mg, 88% yield). Mp: 278 °C dec. 1H NMR (DMSO-d6): δ 3.27 (s, 3H, NCH3), 3.44 (s, 3H, NCH3), 4.02 (s, 3H, N7CH3), 6.78 (d, 1 H, J = 15.4 Hz), 7.55 (d, 1 H, J = 15.4 Hz), 8.4 (br s, 1 H, COOH). MS (CI NH3): m/e 265 (MH+).
Alternately compound 38 was prepared from 39 in DMF/water (1:1) solution by saponification with sodium hydroxide in 49% yield.
8-[trans-2-(tert-Butyloxycarbonyl) vinyl]-1,3,7-trimethylxanthine (39).
A mixture of 8-bromocaffeine (450 mg, 1.65 mmol), tert-butyl acrylate (0.390 mL, 2.69 mmol), Pd(AcO)2 (3.7 mg, 16.5 μmol), tri-o-tolylphosphine (20 mg, 66 μmol), triethylamine (2 mL), and acetonitrile (2 mL) was warmed to 100 °C for 16 h with stirring in a capped tube. After cooling to room temperature, CHC13 was added and the mixture filtered. The organic layer was extracted twice with 1 N HCl, washed with brine several times, dried (MgSO4), and then evaporated to dryness. The residue was treated with MeOH (1 mL), and hexane was added, to afford 152 mg of the crystalline product. The mother liquors were evaporated, and the remaining product was purified by preparative TLC (hexane/ethyl acetate 1:1) to give 49 mg (38% overall). Mp: 214–215 °C. 1H NMR DMSO-d6: δ 1.48 (s, 9H, CH3), 3.22 (s, 3H, NCH3), 3.42 (s, 3H, NCH3), 4.03 (s, 3H, N7CH3), 6.73 (d, 1 H, J = 15 Hz), 7.51 (d, 1 H, J = 15 Hz). MS (CI NH3): m/z 321 (MH+).
6-Amino-5-[[4-(trifluoromethyl)benzoyl]amino]-1,3-di-methyluracil (40).
5,6-Diamino-1,3-dimethyluracil (2.06 g; 10 mmol) was suspended in 20 mL of dry pyridine and then 4-(trifluoromethyl)benzoyl chloride (2 mL, 14 mmol) was added and stirred for 4 h at room temperature. The mixture was then poured into 100 mL of water and the precipitate collected and recrystallized from H2O/EtOH (7:3) to give 2.6 g (85%) of colorless crystals. Mp: 267–269 °C. UV (MeOH): 223 (4.23), 267 (4.29).
6-Amino-5-[[4-(trifluoromethyl)benzoyl]amino]-1,3-di-n-propyluracil Monohydrate (41).
In 10 mL of dry pyridine was dissolved 5,6-diamino-1,3-di-n-propyluracil (2.26 g, 10 mmol) and then after cooling 4-(trifluoromethyl)benzoyl chloride (2 mL, 11.5 mmol) was added slowly with stirring. The mixture was stirred at room temperature overnight and then evaporated and the residue treated with 100 mL of water with stirring until a precipitate was formed. The solid was collected and recrystallized from H2O/EtOH 7:3 to give 3.63 g (90%) of colorless crystals. Mp: 121–123 °C. UV (MeOH): 202 (4.29), 221 (4.20), 268 (4.27).
6-Amino-5-[4-(trifluoromethyl)benzoyl]-N-(methylamino)-1-methyluracil (42).
6-Amino-1-methyl-5-(methylamino)uracil (8.5 g, 0.05 mol) was suspended in 100 mL of dry pyridine, and the mixture was cooled in an ice bath. 4-(Trifluoromethyl)-benzoyl chloride (12 g, 58 mmol) added dropwise with stirring. After stirring for 4 h at room temperature, the mixture was evaporated and the residue treated with 100 mL of water to form a crystalline precipitate. Recrystallization from H2O/MeOH gave 12.45 g (72%) of colorless crystals. Mp: 298–300 °C. UV (MeOH): 205 (4.22), 214 sh (4.15), 267 (4.17).
6-Amino-5-benzoyl-N-(methylamino)-1-methyluracil (43).
A suspension of 6-amino-1-methyl-5-(methylamino)uracil (17 g, 0.1 mol) in 200 mL of dry pyridine was cooled with ice and then benzoyl chloride (16 mL, 0.115 mol) was added dropwise with stirring. The reaction was continued overnight and then evaporated to dryness, and the residue was treated with 200 mL of H2O to form a crystalline precipitate. Recrystallization from H2O/ethanol gave 21 g (76%) of colorless crystals. Mp: >300 °C. UV (MeOH): 203 (4.24), 222 sh (4.05), 268 (4.12).
6-Amino-5-(4-sulfonamidobenzoyl)-N-(methylamino)-1-methyluracil Monohydrate (44).
A suspension of 6-amino-5-(methylamino)-1-methyluracil (17 g, 0.1 mol) in 600 mL of H2O/EtOH 1:1 was treated with 4-sulfamylbenzoic acid (20.1 g, 0.10 mol) and 1,3-dicyclohexylcarbodiimide (25 g, 0.12 mol) at room temperature with stirring. The crystalline precipitate was filtered to yield 2.94 g (83%) of chromatographically pure material. Mp: >300 °C. UV (MeOH): 202 (4.25), 223 (4.22), 266 (4.15).
Biology.
Inhibition of binding of 1 nM [3H]-N6-[(R)-phenylisopropyl]adenosine (NEN, Boston, MA) to A1-receptors in rat brain membranes in rat brain membranes or of 4 nM [3H]CGS 21680 (NEN, Boston, MA) to A2a-receptors in rat striatal membranes was measured as described.22,23 Nonspecific binding was defined for A1-receptors with 10 μM 2-chloroadenosine and for A2a-receptors with 20 μM 2-chloroadenosine. The Ki values were calculated from IC50 values by the method of Cheng and Prusoff24 with KD values of 1 nM for [3H] N6-[(R)-phenylisopropyl]adenosine and 14 nM for [3H] CGS 21680.
Acknowledgment.
The International Life Sciences Institute (Washington, DC) is gratefully acknowledged for support of D.S. and M.M. C.G.-R. thanks the Cystic Fibrosis Foundation for financial support. Project supported in part by SBIR grant 1034AM377-28 to Research Biochemicals.
References
- (1).Jacobson KA; Van Galen PJM; Williams M Adenosine receptors: Pharmacology, structure-activity relationships, and therapeutic potential. J. Med. Chem. 1992, 35, 407–422. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (2).Bruns RF Adenosine antagonism by purines, pteridines and benzopteridines in human fibroblasts. Biochem. Pharmacol. 1981, 30, 325–333. [DOI] [PubMed] [Google Scholar]
- (3).Bruns RF; Daly JW; Snyder SH Adenosine receptor binding: Structure-activity analysis generates extremely potent xanthine antagonists. Proc. Nat. Acad. Sci. U.S.A. 1983, 80, 2072–2080. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (4).Hamilton HW; Ortwine DF; Worth DF; Badger EW; Bristol JA; Bruns RJ; Haleen SJ; Steffen RP Synthesis of xanthines as adenosine antagonists, a practical quantitative structure–activity relationship application. J. Med. Chem. 1985, 28, 1071–1079. [DOI] [PubMed] [Google Scholar]
- (5).Daly JW; Padgett W; Shamim MT; Butts LP; Waters J 1,3-Dialkyl-8-(p-sulfophenyl)xanthines: Potent water-soluble antagonists for A1- and A2-adenosine receptors. J. Med. Chem. 1985, 28, 487–492. [DOI] [PubMed] [Google Scholar]
- (6).Jacobson KA; Kirk KL; Padgett WL; Daly JW Functionalized congeners of 1,3-dialkylxanthines: preparation of analogues with high affinity for adenosine receptors. J. Med. Chem. 1985, 28, 1134–1340. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (7).Daly JW; Padgett WL; Shamim M Analogues of 1,3-dipropyl-8-phenylxanthine: Enhancement of selectivity at A1-adenosine receptors by aryl substituents. J. Med. Chem. 1986, 29, 1520–1524. [DOI] [PubMed] [Google Scholar]
- (8).Jacobson KA; Ukena D; Padgett WL; Daly JW; Kirk KL Xanthine functionalized congeners as potent ligands at A2 adenosine receptors. J. Med. Chem. 1987, 30, 211–214. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (9).Bruns RF; Lu GH; Pugsley TA Characterization of the A2 adenosine receptor labeled by [3H] NECA in rat striatal membranes. Mol. Pharmacol. 1986, 29, 331–346. [PubMed] [Google Scholar]
- (10).Shamim MT; Ukena D; Padgett WL; Hong O; Daly JW 8-Aryl and 8-cycloalkyl-1,3-dipropylxanthines: Further potent and selective antagonists for A1-adenosine receptors. J. Med. Chem. 1988, 31, 613–617. [DOI] [PubMed] [Google Scholar]
- (11).Shamim MT; Ukena D; Padgett WL; Daly JW Effects of 8-phenyl and 8-cycloalkyl substituents on the activity of mono-, di-, and trisubstituted alkylxanthines with substitution at the 1-, 3-, and 7-positions. J. Med. Chem. 1989, 32, 1231–1237. [DOI] [PubMed] [Google Scholar]
- (12).Peet NP; Lentz NL; Meng EC; Dudley MW; Ogden AM; Demeter DA; Weintraub HJ; Bey PA A novel synthesis of xanthines: Support for a new binding mode for xanthines with respect to adenosine at adenosine receptors. J. Med. Chem. 1990, 33, 3127–3130. [DOI] [PubMed] [Google Scholar]
- (13).Martinson EA; Johnson RA; Wells JM Potent adenosine receptor antagonists that are selective for the A1 receptor subtype. Mol. Pharmacol. 1987, 31, 247–252. [PubMed] [Google Scholar]
- (14).Bruns RF; Fergus JH Solubilities of adenosine antagonists determined by radioreceptor assay. J. Pharm. Pharmacol. 1989, 41, 590–594. [DOI] [PubMed] [Google Scholar]
- (15).Daly JW; Padgett WL; Shamim MT Analogues of caffeine and theophylline: Effect of structural alterations on affinity at adenosine receptors. J. Med. Chem. 1986, 29, 1305–1308. [DOI] [PubMed] [Google Scholar]
- (16).Seale T; Abla KA; Shamim MT; Carney JM; Daly JW 3,7-Dimethyl-1-propargylxanthine: A potent and selective in vivo antagonist of adenosine analogs. Life Sci. 1988, 43, 1671–1684. [DOI] [PubMed] [Google Scholar]
- (17).Shimada J; Suzuki F; Monaka H; Ishii A; Ichikawa S (E)-1,3-Dialkyl-7-methyl-8-(3,4,5-trimethoxystyryl)xanthines: Potent and selective adenosine A2 antagonists. J. Med. Chem. 1992, 35, 2342–2345. [DOI] [PubMed] [Google Scholar]
- (18).Jacobson KA; Gallo-Rodriguez C; Melman N; Fischer B; Maillard M; van Bergen A; van Galen PJM; Karton Y Structure-activity relationships of 8-styrylxanthines as A2-selective adenosine antagonists. J. Med. Chem. 1983, 36, 1333–1342. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (19).Nikodijević O; Daly JW; Jacobson KA Characterization of the locomotor depression produced by an A2-selective adenosine agonist. FEBS Lett. 1990, 261, 67–70. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (20).Heller LJ; Olsson RA Inhibition of rat ventricular automaticity by adenosine. Am. J. Physiol. 1985, 248, H907–H913. [DOI] [PubMed] [Google Scholar]
- (21).Baumgold J; Nikodijević O; Jacobson KA Penetration of adenosine antagonists into mouse brain as determined by ex vivo binding. Biochem. Pharmacol. 1992, 43, 889–894. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (22).Jacobson KA; Ukena D; Kirk DL; Daly JW [3H]Xanthine amine congener of 1,3-dipropyl-8-phenylxanthine: An antagonist radioligand for adenosine receptors. Proc. Nat. Acad. Sci. U.S.A. 1986, 83, 4089–4093. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (23).Jarvis MF; Schutz R; Hutchison AJ; Do E; Sills MA; Williams M [3H]CGS 21680, an A2 selective adenosine receptor agonist directly labels A2 receptors in rat brain tissue. J. Pharmacol. Exp. Ther. 1989, 251, 888–893. [PubMed] [Google Scholar]
- (24).Chen YC; Prusoff WH Relationships between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22, 3099–3108. [DOI] [PubMed] [Google Scholar]
- (25).Cortese NA; Ziegler CB; Hrnjez BJ; Heck RF Palladium catalyzed synthesis of 2-quinoline derivatives from 2-iodoanilines. J. Org. Chem. 1978, 43, 2952–2957. [Google Scholar]
